Heart failure is a significant global public health concern affecting millions of individuals. Implantable Left Ventricular Assist Devices (LVADs) have proven beneficial for patients with advanced heart failure who are unresponsive to conventional treatments. However, despite the improved survival rates associated with LVADs, this therapy carries a high risk of recurrent and severe adverse events (AEs) that lead to increased morbidity and mortality. Many clinical studies have examined the AE profiles of LVAD patients, but these studies often focus on statistical analysis and treat each AE as a separate event, overlooking potential relationships and interactions among AEs. This thesis aims to overcome these limitations by exploring three mac...
Cardiovascular diseases, Congestive Heart Failure in particular, are a leading cause of deaths world...
International audienceAims: We tested the hypothesis that a machine learning (ML) algorithm utilizin...
Introduction: Left ventricular ejection fraction (LVEF) ≤35%, as current significant implantable car...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
Heart failure is one of the most common diseases worldwide. In recent years, Ventricular Assist Devi...
Risk models have historically displayed only moderate predictive performance in estimating mortality...
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD)...
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD)...
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD)...
This thesis aims to assess the current body of evidence and experiences with continuous flow-LVADs i...
Use of a left ventricular assist device (LVAD) can benefit patients with end stage heart failure, bu...
Background-Whereas heart failure (HF) is a complex clinical syndrome, conventional approaches to its...
Existing risk assessment tools for patient selection for left ventricular assist devices (LVADs) suc...
<p>Right ventricular failure is a significant complication following implantation of a left ventricu...
Use of a left ventricular assist device (LVAD) can benefit patients with end stage heart failure, bu...
Cardiovascular diseases, Congestive Heart Failure in particular, are a leading cause of deaths world...
International audienceAims: We tested the hypothesis that a machine learning (ML) algorithm utilizin...
Introduction: Left ventricular ejection fraction (LVEF) ≤35%, as current significant implantable car...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
Heart failure is one of the most common diseases worldwide. In recent years, Ventricular Assist Devi...
Risk models have historically displayed only moderate predictive performance in estimating mortality...
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD)...
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD)...
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD)...
This thesis aims to assess the current body of evidence and experiences with continuous flow-LVADs i...
Use of a left ventricular assist device (LVAD) can benefit patients with end stage heart failure, bu...
Background-Whereas heart failure (HF) is a complex clinical syndrome, conventional approaches to its...
Existing risk assessment tools for patient selection for left ventricular assist devices (LVADs) suc...
<p>Right ventricular failure is a significant complication following implantation of a left ventricu...
Use of a left ventricular assist device (LVAD) can benefit patients with end stage heart failure, bu...
Cardiovascular diseases, Congestive Heart Failure in particular, are a leading cause of deaths world...
International audienceAims: We tested the hypothesis that a machine learning (ML) algorithm utilizin...
Introduction: Left ventricular ejection fraction (LVEF) ≤35%, as current significant implantable car...